Medetomidine, known as “rhino tranquilizer,” detected in St. Louis County street drugs, prompting medical warnings

An emerging sedative in an already volatile opioid supply

A veterinary sedative called medetomidine—sometimes referred to on the street as “rhino tranquilizer” or “rhino tranq”—has been detected in illicit drugs circulating in St. Louis County, adding to growing concerns about increasingly complex adulterants mixed into opioids sold as fentanyl or “dope.” Medetomidine belongs to the same drug class as xylazine, another animal tranquilizer that has complicated overdose responses nationwide.

Medetomidine is not approved for human use. In the illicit supply, it has been found in combination with opioids and other substances, and its presence can deepen sedation and suppress breathing—effects that can overlap with, and intensify, opioid toxicity.

What local testing is showing

In the St. Louis region, a drug product and paraphernalia testing initiative jointly run by the Saint Louis County Department of Public Health and a regional forensic toxicology laboratory has been analyzing anonymously sourced samples. The initiative’s stated purpose is to identify changing drug-supply trends and support public health and clinical responses. Recent public-facing technical descriptions of the program identify medetomidine among the substances of concern being tracked locally.

The local detections mirror a broader U.S. pattern documented by federal public health publications and forensic monitoring programs: medetomidine first appeared in North American illicit opioid contexts in 2022 and has since been detected in multiple regions, sometimes alongside xylazine and fentanyl.

Why medetomidine matters during overdoses and withdrawal

Clinicians and public health officials have warned that sedatives mixed into opioids can change how overdoses present and how patients respond to treatment. Naloxone reverses opioid effects, but it does not reverse non-opioid sedatives such as medetomidine or xylazine. That means a person may regain breathing after naloxone yet remain dangerously sedated, or may require prolonged monitoring and supportive care.

Federal reports have also described clusters in other U.S. cities where patients experienced unusual or severe withdrawal syndromes when medetomidine was present in the drug supply. Those cases have contributed to ongoing efforts to update emergency and inpatient protocols as the adulterant landscape evolves.

What public health guidance emphasizes

• Assume illicit opioids may contain multiple sedatives or other adulterants, even when sold under familiar names.

• Use naloxone for suspected opioid overdoses, and call 911; continued sedation after naloxone still requires urgent medical evaluation.

• Extended observation may be necessary when long-acting sedatives are suspected.

• Drug-checking and toxicology surveillance can provide early warning of shifting mixtures, helping tailor harm-reduction messaging and clinical preparedness.

In St. Louis County, the emergence of medetomidine is being treated as a surveillance and preparedness issue: identifying what is in circulation, alerting clinical partners, and adapting responses as the local drug supply changes.

The detection of medetomidine underscores a central reality of the current overdose crisis: risk is increasingly driven not only by fentanyl potency, but also by unpredictable combinations of sedatives and other compounds that can prolong toxicity and complicate treatment.